Literature DB >> 11326026

Comparison of sequence analysis and the INNO-LiPA HBV DR line probe assay for detection of lamivudine-resistant hepatitis B virus strains in patients under various clinical conditions.

S W Aberle1, J Kletzmayr, B Watschinger, B Schmied, N Vetter, E Puchhammer-Stöckl.   

Abstract

A line probe assay (INNO-LiPA HBV DR) detecting drug-resistant hepatitis B virus (HBV) strains was evaluated. Results concordant with sequence analysis were obtained with 48 of 56 serum samples from HBV-infected patients undergoing lamivudine therapy. In eight cases, additional minor subpopulations could be identified by the line probe assay.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11326026      PMCID： PMC88061          DOI： 10.1128/JCM.39.5.1972-1974.2001

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN： 0095-1137            Impact factor:   5.948


  13 in total

1.  Monitoring the virus load can predict the emergence of drug-resistant hepatitis B virus strains in renal transplantation patients during lamivudine therapy.

Authors:  E Puchhammer-Stöckl; C W Mandl; J Kletzmayr; H Holzmann; A Hofmann; S W Aberle; F X Heinz; B Watschinger; H Hofmann
Journal:  J Infect Dis       Date:  2000-05-23       Impact factor: 5.226

2.  Line probe assay for monitoring drug resistance in hepatitis B virus-infected patients during antiviral therapy.

Authors:  L Stuyver; C Van Geyt; S De Gendt; G Van Reybroeck; F Zoulim; G Leroux-Roels; R Rossau
Journal:  J Clin Microbiol       Date:  2000-02       Impact factor: 5.948

3.  Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment.

Authors:  H G Niesters; P Honkoop; E B Haagsma; R A de Man; S W Schalm; A D Osterhaus
Journal:  J Infect Dis       Date:  1998-05       Impact factor: 5.226

4.  A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection.

Authors:  J Main; J L Brown; C Howells; R Galassini; M Crossey; P Karayiannis; P Georgiou; G Atkinson; H C Thomas
Journal:  J Viral Hepat       Date:  1996-07       Impact factor: 3.728

Review 5.  New nucleoside analogues for chronic hepatitis B.

Authors:  S W Schalm; R A de Man; R A Heijtink; H G Niesters
Journal:  J Hepatol       Date:  1995       Impact factor: 25.083

6.  Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine.

Authors:  R Ling; D Mutimer; M Ahmed; E H Boxall; E Elias; G M Dusheiko; T J Harrison
Journal:  Hepatology       Date:  1996-09       Impact factor: 17.425

7.  Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation.

Authors:  M M Bartholomew; R W Jansen; L J Jeffers; K R Reddy; L C Johnson; H Bunzendahl; L D Condreay; A G Tzakis; E R Schiff; N A Brown
Journal:  Lancet       Date:  1997-01-04       Impact factor: 79.321

8.  Two sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine.

Authors:  M I Allen; J Gauthier; M DesLauriers; E J Bourne; K M Carrick; F Baldanti; L L Ross; M W Lutz; L D Condreay
Journal:  J Clin Microbiol       Date:  1999-10       Impact factor: 5.948

9.  Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group.

Authors:  M I Allen; M Deslauriers; C W Andrews; G A Tipples; K A Walters; D L Tyrrell; N Brown; L D Condreay
Journal:  Hepatology       Date:  1998-06       Impact factor: 17.425

10.  A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

Authors:  C L Lai; R N Chien; N W Leung; T T Chang; R Guan; D I Tai; K Y Ng; P C Wu; J C Dent; J Barber; S L Stephenson; D F Gray
Journal:  N Engl J Med       Date:  1998-07-09       Impact factor: 91.245
View more
  13 in total

Review 1.  Antiviral therapies: focus on hepatitis B reverse transcriptase.

Authors:  Eleftherios Michailidis; Karen A Kirby; Atsuko Hachiya; Wangdon Yoo; Sun Pyo Hong; Soo-Ok Kim; William R Folk; Stefan G Sarafianos
Journal:  Int J Biochem Cell Biol       Date:  2012-04-16       Impact factor: 5.085

2.  Application of coamplification at lower denaturation temperature-PCR sequencing for early detection of antiviral drug resistance mutations of hepatitis B virus.

Authors:  Danny Ka-Ho Wong; Ottilia Tsoi; Fung-Yu Huang; Wai-Kay Seto; James Fung; Ching-Lung Lai; Man-Fung Yuen
Journal:  J Clin Microbiol       Date:  2014-06-20       Impact factor: 5.948

3.  European multicenter evaluation of high-density DNA probe arrays for detection of hepatitis B virus resistance mutations and identification of genotypes.

Authors:  N Tran; R Berne; R Chann; M Gauthier; D Martin; M-A Armand; A Ollivet; C G Teo; S Ijaz; D Flichman; M Brunetto; K P Bielawski; C Pichoud; F Zoulim; G Vernet
Journal:  J Clin Microbiol       Date:  2006-08       Impact factor: 5.948

4.  Natural YMDD-motif mutants affect clinical course of lamivudine in chronic hepatitis B.

Authors:  You-Wen Tan; Yun Ye; Guo-Hong Ge; Wei Zhao; Jian-He Gan; Yun Zhao; Zhi-Lin Niu; Dong-Jun Zhang; Li Chen; Xue-Jun Yu; Li-Jun Yang
Journal:  World J Gastroenterol       Date:  2015-02-21       Impact factor: 5.742

5.  Evolution of primary and compensatory lamivudine resistance mutations in chronic hepatitis B virus-infected patients during long-term lamivudine treatment, assessed by a line probe assay.

Authors:  Evelien Libbrecht; Joke Doutreloigne; Hilde Van De Velde; Man-Fung Yuen; Ching-Lung Lai; Fred Shapiro; Erwin Sablon
Journal:  J Clin Microbiol       Date:  2007-10-03       Impact factor: 5.948

6.  Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay.

Authors:  Anna S F Lok; Fabien Zoulim; Stephen Locarnini; Alessandra Mangia; Grazia Niro; Hilde Decraemer; Geert Maertens; Frank Hulstaert; Karen De Vreese; Erwin Sablon
Journal:  J Clin Microbiol       Date:  2002-10       Impact factor: 5.948

7.  Validation of the INNO-LiPA HBV DR assay (version 2) in monitoring hepatitis B virus-infected patients receiving nucleoside analog treatment.

Authors:  H G M Niesters; F Zoulim; C Pichoud; M Buti; F Shapiro; N D'Heuvaert; L Celis; J Doutreloigne; E Sablon
Journal:  Antimicrob Agents Chemother       Date:  2010-01-11       Impact factor: 5.191

Review 8.  Molecular testing in the diagnosis and management of chronic hepatitis B.

Authors:  Alexandra Valsamakis
Journal:  Clin Microbiol Rev       Date:  2007-07       Impact factor: 26.132

9.  Quantitative detection of the M204V hepatitis B virus minor variants by amplification refractory mutation system real-time PCR combined with molecular beacon technology.

Authors:  F Ntziora; D Paraskevis; C Haida; E Magiorkinis; E Manesis; G Papatheodoridis; S Manolakopoulos; A Beloukas; S Chryssoy; G Magiorkinis; V Sypsa; A Hatzakis
Journal:  J Clin Microbiol       Date:  2009-06-24       Impact factor: 5.948

10.  Advances in Molecular Diagnosis of HBV Infection and Drug Resistance.

Authors:  Erwin Sablon; Fred Shapiro
Journal:  Int J Med Sci       Date:  2005-01-05       Impact factor: 3.738
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.